OPKO Health (NASDAQ:OPK) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

OPKO Health (NASDAQ:OPK) released its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09, Zacks reports. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

OPKO Health Trading Down 1.8 %

NASDAQ OPK traded down $0.03 on Thursday, hitting $1.63. The company’s stock had a trading volume of 4,816,978 shares, compared to its average volume of 2,823,192. The company’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.55. OPKO Health has a 52-week low of $0.86 and a 52-week high of $1.76. The firm has a market cap of $1.11 billion, a P/E ratio of -8.58 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock in a transaction on Tuesday, January 28th. The stock was acquired at an average price of $1.47 per share, with a total value of $69,879.39. Following the acquisition, the chief executive officer now owns 213,234,014 shares in the company, valued at approximately $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 1,521,609 shares of company stock worth $2,313,710 over the last three months. Company insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.